X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $34.50 Consensus Price Target from Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned an average recommendation of “Hold” from the five analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $34.50.

XFOR has been the topic of a number of recent research reports. Zacks Research cut X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th. Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research note on Monday, December 29th. Stifel Nicolaus set a $10.00 price target on X4 Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, December 5th. Finally, Wall Street Zen lowered X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th.

X4 Pharmaceuticals Stock Down 1.0%

X4 Pharmaceuticals stock opened at $4.00 on Tuesday. The firm has a 50 day moving average price of $3.81 and a 200-day moving average price of $3.13. The company has a quick ratio of 5.48, a current ratio of 5.65 and a debt-to-equity ratio of 1.23. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $24.43. The company has a market capitalization of $349.76 million, a P/E ratio of -0.40 and a beta of 0.41.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.10. X4 Pharmaceuticals had a negative return on equity of 343.67% and a negative net margin of 279.86%.The business had revenue of $1.77 million for the quarter, compared to the consensus estimate of $2.05 million. As a group, equities analysts predict that X4 Pharmaceuticals will post -0.68 EPS for the current year.

Insider Activity at X4 Pharmaceuticals

In other news, Chairman Adam R. Craig acquired 86,206 shares of the business’s stock in a transaction dated Thursday, October 23rd. The stock was bought at an average cost of $2.90 per share, for a total transaction of $249,997.40. Following the completion of the transaction, the chairman owned 376,087 shares of the company’s stock, valued at $1,090,652.30. The trade was a 29.74% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.37% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of XFOR. Nantahala Capital Management LLC bought a new position in shares of X4 Pharmaceuticals in the third quarter worth $7,621,000. Rosalind Advisors Inc. bought a new position in X4 Pharmaceuticals in the 3rd quarter worth about $5,283,000. Deep Track Capital LP bought a new position in X4 Pharmaceuticals in the 3rd quarter worth about $3,839,000. Kingdon Capital Management L.L.C. raised its holdings in shares of X4 Pharmaceuticals by 300.0% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 933,332 shares of the company’s stock valued at $3,192,000 after acquiring an additional 700,000 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in shares of X4 Pharmaceuticals during the 3rd quarter valued at about $1,176,000. 72.03% of the stock is owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.